Realgar/Indigo naturalis
| Combination of | |
|---|---|
| Realgar | Arsenic compound |
| Indigo naturalis | Traditional Chinese medicine |
| Names | |
| Other names | RIF oral arsenic formulation, Compound Huangdai |
| Clinical data | |
| Routes of use | By mouth |
| Defined daily dose | not established[1] |
| Legal | |
| Legal status |
|
Realgar/Indigo naturalis (RIF), also known as Compound Huangdai, is a medication used to treat acute promyelocytic leukemia.[2] Effectiveness appears similar to arsenic trioxide.[2] It is generally used together with all-trans-retinoic acid (ATRA).[2] It is taken by mouth.[3]
Side effects may include abdominal pain and rash.[2] It is made up of a combination of realgar (tetra-arsenic tetra-sulfide), Indigo naturalis, root of Salvia miltiorrhiza, and root of Pseudostellaria heterophylla.[2] It works by breaking down the cancer protein retinoic acid receptor alpha.[4]
Realgar-Indigo naturalis was developed in the 1980s and approved for medical use in China in 2009.[2][5] It is on the World Health Organization's List of Essential Medicines.[3] It is made in China and was originally a herbal remedy.[2] It is not very expensive.[2] It is not approved in either the United States or Europe as of 2019.[2]
Dosage
The defined daily dose is not established.[1]
References
- ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 10 September 2020. CS1 maint: discouraged parameter (link)
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Proposal for the inclusion of arsenic therapies in the WHO Model list of ESSENTIAL MEDICINES for the treatment of acute promyelocytic leukemia" (PDF). WHO. Retrieved 15 November 2019. CS1 maint: discouraged parameter (link)
- ↑ 3.0 3.1 World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "realgar-Indigo naturalis formulation". National Cancer Institute. 2 February 2011. Retrieved 15 November 2019. CS1 maint: discouraged parameter (link)
- ↑ Ghosh, Dilip; Smarta, R. B. (2016). Pharmaceuticals to Nutraceuticals: A Shift in Disease Prevention. CRC Press. p. PT41. ISBN 9781315354934.
External links
| Identifiers: |
|---|
- CS1 maint: discouraged parameter
- Articles with short description
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Arsenic compounds
- Cancer treatments
- World Health Organization essential medicines